GlassScriptPhysician profile
Karin A Beals
NPI 1386981413
$4,247.74
in general payments reported to CMS, 2019-2025
31 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $546 · 2023: $1,113 · 2024: $1,278 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,189.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $744.17 | 2022-2025 | |
| Abbvie INC. | $530.17 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.37 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $216.02 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.12 | 2024-2025 | Caplyta |
| Abbott Laboratories | $122.22 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $98.61 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $95.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Corium, LLC | $92.27 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $81.74 | 2023-2024 | Rexulti, Abilify Maintena |
| Dexcom, INC. | $77.49 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.29 | 2022-2024 | Jardiance |
| Amgen INC. | $64.67 | 2022-2025 | Evenity, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $52.84 | 2025 | Gemtesa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.67 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $38.66 | 2023 | |
| Lundbeck LLC | $38.30 | 2024 | Vyepti, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.14 | 2023 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $30.95 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $27.64 | 2022-2024 | Eliquis |
| Collegium Pharmaceutical, INC. | $18.11 | 2025 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $18.09 | 2025 | |
| Ardelyx, INC. | $17.68 | 2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $16.44 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $15.61 | 2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $15.52 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.08 | 2023 | Trintellix |
| Currax Pharmaceuticals LLC | $14.04 | 2024 | Contrave, Onzetra Xsail |
| Janssen Pharmaceuticals, INC | $13.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.61 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Beals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.